title: Hepatitis viruses and liver transplantation: evolving trends in antiviral management.
abstract: Viral hepatitis is both a leading indication for liver transplant (LT) and an important cause of posttransplant graft loss and mortality. Treatment and prevention of hepatitis B virus in LT recipients, with the observed corresponding improvement in post-LT outcomes, is among the great success stories in transplantation. By comparison, treatment of hepatitis C virus with safe and effective regimens is only just becoming a reality. Chronic hepatitis E virus infection in LT recipients represents a newly described phenomenon that can also lead to graft loss; early diagnosis and treatment may be key in the management of these patients.
authors.affiliation: Division of Digestive and Liver Diseases, Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, 622 West 168th Street, New York, NY 10032, USA. Electronic address: ev77@columbia.edu.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Verna
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D046148:Donor Selection; D058625:End Stage Liver Disease / Q000209:etiology / Q000601:surgery*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy; D016751:Hepatitis E / Q000150:complications / Q000188:drug therapy; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000639:trends*; D012008:Recurrence; D014850:Waiting Lists
chemical_list: D000998:Antiviral Agents
keywords: Antiviral therapy; HBV; HCV; HEV; Liver transplant